WO2003095029A1 - Bisphosphonic acid for the treatment and prevention of osteoporosis - Google Patents

Bisphosphonic acid for the treatment and prevention of osteoporosis Download PDF

Info

Publication number
WO2003095029A1
WO2003095029A1 PCT/EP2003/004629 EP0304629W WO03095029A1 WO 2003095029 A1 WO2003095029 A1 WO 2003095029A1 EP 0304629 W EP0304629 W EP 0304629W WO 03095029 A1 WO03095029 A1 WO 03095029A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
acceptable salt
bisphosphonic acid
acid
medicament
Prior art date
Application number
PCT/EP2003/004629
Other languages
French (fr)
Inventor
Frieder Bauss
Bernhard Pichler
Stephen Turley
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29414669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003095029(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to KR1020137034838A priority Critical patent/KR20140021045A/en
Priority to JP2004503108A priority patent/JP2005522526A/en
Priority to KR1020157010154A priority patent/KR20150053811A/en
Priority to MXPA04009586A priority patent/MXPA04009586A/en
Priority to NZ535705A priority patent/NZ535705A/en
Priority to AU2003229770A priority patent/AU2003229770B2/en
Priority to SI200331018T priority patent/SI1506041T1/en
Priority to EP03722591A priority patent/EP1506041B1/en
Priority to DK03722591T priority patent/DK1506041T3/en
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to CA2481142A priority patent/CA2481142C/en
Priority to BR0308901-0A priority patent/BR0308901A/en
Priority to DE60317061T priority patent/DE60317061T2/en
Priority to KR1020097019891A priority patent/KR20090106663A/en
Priority to KR1020047015694A priority patent/KR100642961B1/en
Publication of WO2003095029A1 publication Critical patent/WO2003095029A1/en
Priority to IL17437104A priority patent/IL164371A0/en
Priority to HR20040906 priority patent/HRP20040906B1/en
Priority to NO20044195A priority patent/NO328734B1/en
Priority to ZA2004/07950A priority patent/ZA200407950B/en
Priority to IL164371A priority patent/IL164371A/en
Priority to HK06100194.8A priority patent/HK1080409A1/en
Priority to NO20100477A priority patent/NO331024B1/en
Priority to IL205262A priority patent/IL205262A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Definitions

  • the present invention refers to the use of bisphosphonic acids, especially of (1- hydroxy-3-(N-methyl-N-pentyl)aminopropylidene-l,l-bisphosphonic acid
  • Bones serve mainly as a support, and consequently bone is frequently regarded as a simple building material. However, bone is a complicated biomaterial adapted to a wide variety of requirements, stimuli and noxae to which it is exposed. Endoprostheses are available as substitutes for bones and joints. However endoprostheses, even when biomechanically highly refined, do not have an active effect on the environmental and load factors.
  • disorders in humans and mammals involve or are associated with abnormal bone resorption.
  • Such disorders include, but are not limited to, osteoporosis, Paget's disease, periprosthetic bone loss or osteolysis, and hypercalcemia of malignancy and metastatic bone disease.
  • the most common of these disorders is osteoporosis, which in its most frequent manifestation occurs in postmenopausal women.
  • osteoporosis as well as other disorders associated with bone loss, are chronic conditions, it is believed that appropriate therapy will generally require chronic treatment.
  • Bisphosphonates i.e. bisphosphonic acids or pharmaceutically acceptable salts thereof, are synthetic analogs of the naturally occurring pyrophosphate. Due to their marked affinity for solid-phase calcium phosphate, bisphosphonates bind strongly to bone mineral.
  • Pharmacologically active bisphosphonates are well known in the art and are potent inhibitors of bone resorption and are therefore useful in the treatment and prevention of diseases involving abnormal bone resorption, especially osteoporosis, Paget's disease, hypercalcemia of malignancy, and metastatic and metabolic bone diseases.
  • Bisphosphonates as pharmaceutical agents are described for example in EP-A- 170,228, EP-A-197,478, EP-A-22,751; EP-A-252,504, EP-A- 252,505, EP-A-258,618, EP-A-350,002, EP-A-273,190, WO-A-90/00798, etc., each of which are incorporated herein by reference.
  • bisphosphonates are oral formulations (tablets or capsules) or solutions for intravenous injection or infusion. They are systemically well tolerated when administered at therapeutic doses.
  • bisphosphonates as a class are irritant to skin and mucous membranes and when given orally on a continuous basis may result in digestive tract side effects, e.g. esophageal adverse events or gastrointestinal disturbances.
  • the oral route of administration has, to date, had to follow inconvenient recommendations of use for the patient.
  • Bisphosphonates can be classified into two groups with different modes of action. Ibandronate belongs to the more potent nitrogen- containing bisphosphonates [Russell 1999 Russell RGG, Rogers MJ. Bisphosphonates: From the laboratory to the clinic and back again. Bone 25(1):97-106 (1999); Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen ⁇ , Frith JC. Cellular Molecular mechanisms of action of bisphosphonates. Cancer 88 (12) Sup ⁇ l:2961-2978 (2000)]. Ibandronate is one of the most potent bisphosphonates currently under clinical development in osteoporosis and metastatic bone diseases.
  • ibandronate is 2,10, 50 and 500 times more potent than risedronate, alendronate, pamidronate, and clodronate respectively [M ⁇ hlbauer R.C., F. Bauss, R. Schenk, M. Janner, E. Bosies, K. Strein, and H. Fleisch. BM 21.0955 a potent new bisphosphonate to inhibit bone resorption. J. Bone Miner. Res. 6: 1003 - 1011 (1991)].
  • Ibandronate inhibits bone resorption without any impairment of mineralisation (M ⁇ hlbauer et al M ⁇ hlbauer R.C., F. Bauss, R. Schenk, M. Janner, E. Bosies, K. Strein, and H. Fleisch.BM 21.0955 a potent new bisphosphonate to inhibit bone resorption. J. Bone Miner. Res. 6: 1003 - 1011 (1991).). It has been shown to decrease osteoclastic activity thus inhibiting bone destruction. At high doses it also reduces the number of osteoclasts (M ⁇ hlbauer et al. M ⁇ hlbauer R.C., F. Bauss, R. Schenk, M. Janner, E. Bosies, K. Strein, and H. Fleisch.BM 21.0955 a potent new bisphosphonate to inhibit bone resorption. J. Bone Miner. Res. 6: 1003 - 1011 (1991)).
  • the present invention is thus concerned with the use of a bisphosphonic acid or a pharmaceutical acceptable salt thereof , especially with the use of ibandronic acid or a pharmaceutical acceptable salt thereof, for the preparation of medicaments for the prevention or the treatment of disorders characterized by pathologically increased bone resorption, wherein the medicament a) comprises about 50 to 250 mg, preferably about 100 to 150 mg of a bisphosphonic acid or a acceptable salt thereof and b) the medicament is orally administered on one, two or three consecutive days per month.
  • the present invention relates to the use of bisphosphonic acids or pharmaceutically acceptable salts, especially ibandronic acid or pharmaceutically acceptable salts thereof for the manufacture of a medicament for the prevention or treatment of disorders characterized by pathologically increased bone resorption, e.g. osteoporosis, wherein the medicament comprises at least 120% of the expected efficacious daily dose of a bisphosphonic acids or acceptable salts thereof and is administered on one, two or three consecutive days per month.
  • the invention comprises the use of ibandronic acid or pharmaceutically acceptable salts thereof for the manufacture of a medicament for the prevention or the treatment of disorders characterized by pathologically increased bone resorption wherein the medicament a) comprises about 100 to about 150 mg of ibandronic acid or a pharmaceutically acceptable salt thereof and b) is orally administered on one, two or three consecutive days per month.
  • bisphosphonic acid means compounds characterized by two phosphonate groups linked by phosphoether bonds to a central (geminal) carbon atom. Such a P-C-P structure is exemplified in Formula I below.
  • bisphosphonic acids as used herein in referring to the therapeutic agents of the present invention are meant to also encompass bisphosphonates, biphosphonic acids, and bisphosphonic acids, as well as salts and derivatives of these materials.
  • the use of a specific nomenclature in referring to the bisphosphonate or bisphosphonates is not meant to limit the scope of the present invention, unless specifically indicated.
  • pharmaceutically acceptable means that the salts or chelating agents are acceptable from a toxicity viewpoint.
  • pharmaceutically acceptable salt refers to ammonium salts, alkali metal salts such as potassium and sodium (including mono, di- and tri-sodium) salts (which are preferred), alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.
  • disorders characterized by pathologically increased bone resorption refers to medically defined conditions withor without identifiable cause (such as postmenopausal osteoporosis, idiopathic juvenile osteoporosis, osteoporosis associated with Klinefelter's syndrome, male osteoporosis, osteoporosis due to nutritional factors, organ transplant related osteoporosis, immobilisation associated osteoporosis, inflammatory condition and cortico-steroid induced osteoporosis).
  • one, two or three consecutive days per month means administration of one to three dose proportional or non-dose proportional tablets on one, two or three consecutive days of the month, preferably on one day per month.
  • month is used in accordance with the generally accepted meaning as a measure of time amounting to approximately four (4) weeks, approximately 30 days, or approximately V ⁇ 2 of a calendar year.
  • the term “medicament” refers to a pharmaceutical composition.
  • the term encompasses single or multiple administration schemes.
  • the medicament is administered on one day per month.
  • the medicament is administered as a single dose, however, the scope of the present invention includes medicaments administered as multiple sub-doses such as on two consecutive day per month or on three consecutive days per month.
  • the medicament comprises at least 100%, preferably 120% to 200%, most preferred 120% to 150% of the efficacious dose of bisphosphonic acids or pharmaceutically acceptable salts thereof, more preferably of ibandronic acid or pharmaceutically acceptable salts thereof.
  • efficacious dose refers to about 50 to about 250 mg, more preferably to about 100 to about 150 mg, of a bisphosphonate or a pharmaceutically acceptable salt thereof for example of ibandronic acid or a pharmaceutically acceptable salt thereof.
  • the efficacious dose may be a single dose or multiple sub-doses.
  • the dose maybe one (1) 150 mg dose, two (2) 75 mg sub-doses administered on one day or on two consecutive days, or three (3) 50 mg sub-doses administered on one day or on two or three consecutive days;
  • the efficacious dose is 100 mg, the dose may include one (1) 100 mg dose, two (2) 50 mg sub-doses administered on one day or two consecutive days, preferably on two consecutive days.
  • base salts of bisphosphonic acids include ammonium salts, alkali metal salts such as potassium and sodium (including mono, di- and tri-sodium) salts (which are preferred), alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.
  • the non-toxic, physiologically acceptable salts are preferred.
  • the salts may be prepared by methods known in the art, such as described in European Patent Application 252,504 or in US Patent No. 4,922,077, incorporated herein by reference.
  • the medicament comprises 100 to 150 mg of a ibandronic acid or a pharmaceutically acceptable salt thereof.
  • the medicament is administered as a single dose.
  • bisphosphonate of the present invention corresponds to compounds of general formula
  • a and X are independently selected from the group consisting of hydrogen, hydroxy, halogen, amino, SH, phenyl, alkyl, mono- or dialkylamino, mono- or dialkylaminoalkyl, alkoxy, hioalkyl, thiophenyl, and aryl or heteroaryl moieties selected from the group consisting of phenyl, pyridyl, furanyl, pyrrolidinyl, imidazolyl, and benzyl, wherein the aryl or heteroaryl moiety is optionally substituted with alkyl.
  • A can include X and X include A such that the two moieties can form part of the same cyclic structure.
  • the foregoing chemical formula is also intended to encompass carbocyclic, aromatic and heteroaromatic structures for the A and/or X substituents, e.g. naphthyl, quinolyl, isoquinolyl, adamantyl, and chlorophenyl hio.
  • Preferred structures are those in which A is selected from the group consisting of hydrogen, hydroxy, and halogen, an X is selected from the group consisting of alkyl, halogen, thiophenyl, hioalkyl and dialkylaminoalkyl.
  • More preferred structures are those in which A is selected from the group consisting of hydrogen, hydroxy, and Cl and X is selected from the group consisting of alkyl, Cl, chlorophenylfhio and dialkylaminoalkyl.
  • the preferred bisphosphonic acid or pharmaceutically acceptable salt is selected from the group consisting of alendronate, cimadronate, clodronate, EB-1053, tiludronate, etidronate, ibandronate, incadronate, minodronate, neridronate, olpadronate, risedronate, piridronate, pamidronate, zolendronate or acceptable salts thereof, e.g. ibandronic acid, monosodium salt, monohydrate.
  • Ibandronic acid l-hydroxy-3-(N-methyl-N-pentyl)aminopropylidene-l,l- bisphosphonic acid
  • physiologically compatible salts thereof are particularly preferred, e.g. ibandronic acid, monosodium salt, monohydrate.
  • the bisphosphonates and pharmaceutically acceptable salts may be administered alone or in combination with other bone active drugs, either in fixed combinations or separately both physically and in time, including hormones, such as a steroid hormone, e.g. an estrogen; a partial estrogen agonist, or estrogen-gestagen combination; a calcitonin or analogue or derivative thereof, e.g. salmon, eel or human calcitonin parathyroid hormone or analogues thereof, e.g. PTH (1-84), PTH (1-34), PTH (1-36), PTH (1-38), PTH (1-31)NH2 or PPTS 893; a SERM (Selective Estrogen Receptor Modulator), e.g. raloxifene, lasofoxifene, TSE-434, FC1271, tibolone, vitamin D or an analog.
  • hormones such as a steroid hormone, e.g. an estrogen; a partial estrogen agonist, or estrogen-gestagen combination; a
  • compositions are known in the art and have been described e.g. in US Patent Nos. 6,143,326 and 6,294,196, herein incorporated by reference.
  • the compounds of the present invention may be admixed with pharmaceutically inert, inorganic or organic excipients.
  • suitable excipients for tablets, dragees or hard gelatine capsules include lactose, maize starch or derivatives thereof, talc or stearic acid or salts thereof.
  • compositions may also contain preserving agents, solubilising agents, stabilizing agents, wetting agents, emulsifiers, sweeteners, colorants, odorants, salts for the variation of osmotic pressure, buffers, coating agents or antioxidants. They may also contain other therapeutically valuable agents.
  • the pharmaceutical composition is a film coated tablet wherein the tablet core comprises 50 to 200 mg of a bisphosphonic acid or a pharmaceutically acceptable salt thereof as defined above and one or more pharmaceutically acceptable excipients selected from the group consisting of lactose, polyvinylpyrrolidone, macrocrystalline cellulose, crospovidone, stearic acid, silicon dioxide and the tablet core comprises one or more pharmaceutically acceptable excipients selected from the group consisting of hydroxypropyl methylcellulose, titanium dioxide, talc and polyethylene glycol 6000.
  • these compositions are known in the art and described for example in US Patent Nos. 6,143,326 and 6,294,196.
  • Another aspect of the present invention is a method for treating, reducing or preventing disorders characterized by pathologically increased bone resorption comprising to a mammal administration of an effective amount of bisphosphonic acids or acceptable salts thereof.
  • the invention refers to a method for treating, reducing or preventing disorders characterized by pathologically increased bone resorption comprising oral administration of an effective amount of a bisphosphonic acid or a pharmaceutically acceptable salt thereof, wherein approximately 50 to 250 mg bisphosphonic acid or a pharmaceutically acceptable salt thereof are administered on one, two or three consecutive days per month.
  • the effective amount of bisphosphonic acid or pharmaceutically acceptable salt thereof may be administered as a single dose or as multiple sub-doses.
  • the method comprises administration of about 50 to 250 mg, preferably about 100 to 150 mg, of a bisphosphonate or a pharmaceutically acceptable salt thereof on one, two or three consecutive days per month.
  • the method includes administration of the dose through multiple sub-dosing, the preferred method provides a single dose.
  • Examples for administration of the dose through multiple sub-dosing are as follows, if the efficacious dose is 150 mg, the dose may be two (2) 75 mg sub-doses administered on one day or on two consecutive days, or three (3) 50 mg sub-doses administered on one day or on two or three consecutive days; if the efficacious dose is 100 mg, the dose maybe two (2) 50 mg sub-doses administered on one day or two consecutive days, preferably on two consecutive days.
  • the preferred bisphosphonate is ibandronate or a pharmaceutically acceptable salt thereof, e.g. ibandronic acid, monosodium salt, monohydrate.
  • the bisphosphonic acid is selected from the group consisting of alendronate, cimadronate, clodronate, EB-1053, tiludronate, etidronate, ibandronate, incadronate, minodronate, neridronate, olpadronate, risedronate, piridronate, pamidronate, zolendronate or pharmaceutical acceptable salts thereof. More preferably, the bisphosphonic acid is ibandronate or a pharmaceutically acceptable salt thereof, e.g. ibandronic acid, monosodium salt, monohydrate.
  • the Example shows the composition of a 50 mg tablet.
  • the composition and preparation of these tablets is known in the art and described for example in US Patent Nos. 6,143,326 and 6,294,196.
  • compositions maybe prepared by adjusting the ingredients according to the amount of bisphosphonate, e.g. ibandronic acid, monosodium salt, monohydrate.

Abstract

The present invention refers to the use of bisphosphonic acids or pharmaceutically acceptable salts thereof for the manufacture of medicaments for the prevention or the treatment of disorders characterized by pathologically increased bone resorption, especially for the prevention and treatment of osteoporosis.

Description

BISPHOSPHONIC ACIDS FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS
The present invention refers to the use of bisphosphonic acids, especially of (1- hydroxy-3-(N-methyl-N-pentyl)aminopropylidene-l,l-bisphosphonic acid
(ibandronic acid) or pharmaceutically acceptable salts thereof for the manufacture of medicaments for the prevention or the treatment of disorders characterized by pathologically increased bone resorption, especially for the prevention and treatment of osteoporosis.
Bones serve mainly as a support, and consequently bone is frequently regarded as a simple building material. However, bone is a complicated biomaterial adapted to a wide variety of requirements, stimuli and noxae to which it is exposed. Endoprostheses are available as substitutes for bones and joints. However endoprostheses, even when biomechanically highly refined, do not have an active effect on the environmental and load factors.
A variety of disorders in humans and mammals involve or are associated with abnormal bone resorption. Such disorders include, but are not limited to, osteoporosis, Paget's disease, periprosthetic bone loss or osteolysis, and hypercalcemia of malignancy and metastatic bone disease. The most common of these disorders is osteoporosis, which in its most frequent manifestation occurs in postmenopausal women. Because osteoporosis, as well as other disorders associated with bone loss, are chronic conditions, it is believed that appropriate therapy will generally require chronic treatment. Bisphosphonates, i.e. bisphosphonic acids or pharmaceutically acceptable salts thereof, are synthetic analogs of the naturally occurring pyrophosphate. Due to their marked affinity for solid-phase calcium phosphate, bisphosphonates bind strongly to bone mineral. Pharmacologically active bisphosphonates are well known in the art and are potent inhibitors of bone resorption and are therefore useful in the treatment and prevention of diseases involving abnormal bone resorption, especially osteoporosis, Paget's disease, hypercalcemia of malignancy, and metastatic and metabolic bone diseases.
Bisphosphonates as pharmaceutical agents are described for example in EP-A- 170,228, EP-A-197,478, EP-A-22,751; EP-A-252,504, EP-A- 252,505, EP-A-258,618, EP-A-350,002, EP-A-273,190, WO-A-90/00798, etc., each of which are incorporated herein by reference.
Pharmaceutical forms of currently marketed bisphosphonates are oral formulations (tablets or capsules) or solutions for intravenous injection or infusion. They are systemically well tolerated when administered at therapeutic doses. However, bisphosphonates as a class are irritant to skin and mucous membranes and when given orally on a continuous basis may result in digestive tract side effects, e.g. esophageal adverse events or gastrointestinal disturbances. In consequence, and due to their low oral bioavailability, the oral route of administration has, to date, had to follow inconvenient recommendations of use for the patient.
Bisphosphonates can be classified into two groups with different modes of action. Ibandronate belongs to the more potent nitrogen- containing bisphosphonates [Russell 1999 Russell RGG, Rogers MJ. Bisphosphonates: From the laboratory to the clinic and back again. Bone 25(1):97-106 (1999); Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen }, Frith JC. Cellular Molecular mechanisms of action of bisphosphonates. Cancer 88 (12) Supρl:2961-2978 (2000)]. Ibandronate is one of the most potent bisphosphonates currently under clinical development in osteoporosis and metastatic bone diseases. In animal models of bone resorption, ibandronate is 2,10, 50 and 500 times more potent than risedronate, alendronate, pamidronate, and clodronate respectively [Mϋhlbauer R.C., F. Bauss, R. Schenk, M. Janner, E. Bosies, K. Strein, and H. Fleisch. BM 21.0955 a potent new bisphosphonate to inhibit bone resorption. J. Bone Miner. Res. 6: 1003 - 1011 (1991)].
Ibandronate inhibits bone resorption without any impairment of mineralisation (Mϋhlbauer et al Mϋhlbauer R.C., F. Bauss, R. Schenk, M. Janner, E. Bosies, K. Strein, and H. Fleisch.BM 21.0955 a potent new bisphosphonate to inhibit bone resorption. J. Bone Miner. Res. 6: 1003 - 1011 (1991).). It has been shown to decrease osteoclastic activity thus inhibiting bone destruction. At high doses it also reduces the number of osteoclasts (Mϋhlbauer et al. Mϋhlbauer R.C., F. Bauss, R. Schenk, M. Janner, E. Bosies, K. Strein, and H. Fleisch.BM 21.0955 a potent new bisphosphonate to inhibit bone resorption. J. Bone Miner. Res. 6: 1003 - 1011 (1991)).
As described, bisphosphonates are accepted as providing strong efficacy in the management of osteoporosis. However, given the administration restrictions related to low oral bioavailability and potential for gastro-intestinal effects, there is a clear opportunity for regimens which offer improved convenience and flexibility, leading to a higher level of compliance and superior patient management / satisfaction. Intermittend regimens such as for example once weekly administration have been described in the art, but such intermittent treatments do not result in the desired results.
It has now been found that the prevention or the treatment of disorders characterized by pathologically increased bone resorption such as osteoporosis, can be improved by a monthly administration of 50 to 250 mg of a bisphosphonate or pharmaceutical acceptable salt thereof, especially by a monthly administration of ibandronate, i.e. ibandronic acid or a pharmaceutically acceptable salt thereof.
The present invention is thus concerned with the use of a bisphosphonic acid or a pharmaceutical acceptable salt thereof , especially with the use of ibandronic acid or a pharmaceutical acceptable salt thereof, for the preparation of medicaments for the prevention or the treatment of disorders characterized by pathologically increased bone resorption, wherein the medicament a) comprises about 50 to 250 mg, preferably about 100 to 150 mg of a bisphosphonic acid or a acceptable salt thereof and b) the medicament is orally administered on one, two or three consecutive days per month.
Monthly oral treatment by administration of at least 120%, especially of 120% to 200% of the expected dose offers incremental patient benefits with respect to convenience and compliance as well as superior results. The "expected dose" (100%) corresponds to the cumulated efficacious daily doses. Prior to the completion of the ibandronate clinical development program, no bisphosphonate had prospectively demonstrated fracture reduction efficacy with a drug- ree interval beyond daily administration. In summary, it is quite unexpected that fracture reduction benefit can be derived from a monthly administration of an oral bisphosphonate with a single or multiple tablet administration scheme.
Accordingly, the present invention relates to the use of bisphosphonic acids or pharmaceutically acceptable salts, especially ibandronic acid or pharmaceutically acceptable salts thereof for the manufacture of a medicament for the prevention or treatment of disorders characterized by pathologically increased bone resorption, e.g. osteoporosis, wherein the medicament comprises at least 120% of the expected efficacious daily dose of a bisphosphonic acids or acceptable salts thereof and is administered on one, two or three consecutive days per month.
More preferably the invention comprises the use of ibandronic acid or pharmaceutically acceptable salts thereof for the manufacture of a medicament for the prevention or the treatment of disorders characterized by pathologically increased bone resorption wherein the medicament a) comprises about 100 to about 150 mg of ibandronic acid or a pharmaceutically acceptable salt thereof and b) is orally administered on one, two or three consecutive days per month.
The term "bisphosphonic acid" means compounds characterized by two phosphonate groups linked by phosphoether bonds to a central (geminal) carbon atom. Such a P-C-P structure is exemplified in Formula I below. It should be noted that the term "bisphosphonic acids" as used herein in referring to the therapeutic agents of the present invention are meant to also encompass bisphosphonates, biphosphonic acids, and bisphosphonic acids, as well as salts and derivatives of these materials. The use of a specific nomenclature in referring to the bisphosphonate or bisphosphonates is not meant to limit the scope of the present invention, unless specifically indicated.
The term "pharmaceutically acceptable" as used herein means that the salts or chelating agents are acceptable from a toxicity viewpoint.
The term "pharmaceutically acceptable salt" refers to ammonium salts, alkali metal salts such as potassium and sodium (including mono, di- and tri-sodium) salts (which are preferred), alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. The term "disorders characterized by pathologically increased bone resorption" refers to medically defined conditions withor without identifiable cause (such as postmenopausal osteoporosis, idiopathic juvenile osteoporosis, osteoporosis associated with Klinefelter's syndrome, male osteoporosis, osteoporosis due to nutritional factors, organ transplant related osteoporosis, immobilisation associated osteoporosis, inflammatory condition and cortico-steroid induced osteoporosis).
The term "one, two or three consecutive days per month" means administration of one to three dose proportional or non-dose proportional tablets on one, two or three consecutive days of the month, preferably on one day per month. As used herein, the term "month" is used in accordance with the generally accepted meaning as a measure of time amounting to approximately four (4) weeks, approximately 30 days, or approximately Vι2 of a calendar year.
The term "medicament" refers to a pharmaceutical composition. The term encompasses single or multiple administration schemes.
Preferably the medicament is administered on one day per month. Preferably, the medicament is administered as a single dose, however, the scope of the present invention includes medicaments administered as multiple sub-doses such as on two consecutive day per month or on three consecutive days per month.
Preferably, the medicament comprises at least 100%, preferably 120% to 200%, most preferred 120% to 150% of the efficacious dose of bisphosphonic acids or pharmaceutically acceptable salts thereof, more preferably of ibandronic acid or pharmaceutically acceptable salts thereof.
The term " efficacious dose" refers to about 50 to about 250 mg, more preferably to about 100 to about 150 mg, of a bisphosphonate or a pharmaceutically acceptable salt thereof for example of ibandronic acid or a pharmaceutically acceptable salt thereof. As noted, the efficacious dose may be a single dose or multiple sub-doses. For example, if the efficacious dose is 150 mg, the dose maybe one (1) 150 mg dose, two (2) 75 mg sub-doses administered on one day or on two consecutive days, or three (3) 50 mg sub-doses administered on one day or on two or three consecutive days; if the efficacious dose is 100 mg, the dose may include one (1) 100 mg dose, two (2) 50 mg sub-doses administered on one day or two consecutive days, preferably on two consecutive days. "Bisphosphonic acids and pharmaceutically acceptable salts thereof as pharmaceutical agents are described for example in US Patent Nos. 4,509,612, 4,666,895, 4,719,203, 4,777,163, 5,002,937, 4,971,958 and 4,958,839 and in European Patent Applications Nos. 252,504 and 252,505, herein incorporated by reference for such description.
Methods for the preparation of bisphosphonic acids and pharmaceutically acceptable salts thereof may be found in, e.g., US Patent Nos. 3,962,432, 4,054,598, 4,267,108, 4,327,039, 4,407,761, 4,621,077, 4,624,947, 4,746,654, 4,922,077, 4,970,335, 5,019,651, 4,761,406, 4,876,248; in J. Org. Chem. 32, 4111 (1967) and European Patent Application 252,504, herein incorporated by reference. The pharmaceutically acceptable salts of bisphosphonic acids may also be employed in the instant invention. Examples of base salts of bisphosphonic acids include ammonium salts, alkali metal salts such as potassium and sodium (including mono, di- and tri-sodium) salts (which are preferred), alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. The non-toxic, physiologically acceptable salts are preferred. The salts may be prepared by methods known in the art, such as described in European Patent Application 252,504 or in US Patent No. 4,922,077, incorporated herein by reference.
Preferably, the medicament comprises 100 to 150 mg of a ibandronic acid or a pharmaceutically acceptable salt thereof. Preferably, the medicament is administered as a single dose.
In a preferred embodiment of the present invention, the term "bisphosphonate" of the present invention corresponds to compounds of general formula
Figure imgf000007_0001
wherein A and X are independently selected from the group consisting of hydrogen, hydroxy, halogen, amino, SH, phenyl, alkyl, mono- or dialkylamino, mono- or dialkylaminoalkyl, alkoxy, hioalkyl, thiophenyl, and aryl or heteroaryl moieties selected from the group consisting of phenyl, pyridyl, furanyl, pyrrolidinyl, imidazolyl, and benzyl, wherein the aryl or heteroaryl moiety is optionally substituted with alkyl. In the foregoing chemical formula, A can include X and X include A such that the two moieties can form part of the same cyclic structure.
The foregoing chemical formula is also intended to encompass carbocyclic, aromatic and heteroaromatic structures for the A and/or X substituents, e.g. naphthyl, quinolyl, isoquinolyl, adamantyl, and chlorophenyl hio.
Preferred structures are those in which A is selected from the group consisting of hydrogen, hydroxy, and halogen, an X is selected from the group consisting of alkyl, halogen, thiophenyl, hioalkyl and dialkylaminoalkyl.
More preferred structures are those in which A is selected from the group consisting of hydrogen, hydroxy, and Cl and X is selected from the group consisting of alkyl, Cl, chlorophenylfhio and dialkylaminoalkyl.
The preferred bisphosphonic acid or pharmaceutically acceptable salt is selected from the group consisting of alendronate, cimadronate, clodronate, EB-1053, tiludronate, etidronate, ibandronate, incadronate, minodronate, neridronate, olpadronate, risedronate, piridronate, pamidronate, zolendronate or acceptable salts thereof, e.g. ibandronic acid, monosodium salt, monohydrate.
Ibandronic acid ( l-hydroxy-3-(N-methyl-N-pentyl)aminopropylidene-l,l- bisphosphonic acid) or physiologically compatible salts thereof are particularly preferred, e.g. ibandronic acid, monosodium salt, monohydrate.
The bisphosphonates and pharmaceutically acceptable salts may be administered alone or in combination with other bone active drugs, either in fixed combinations or separately both physically and in time, including hormones, such as a steroid hormone, e.g. an estrogen; a partial estrogen agonist, or estrogen-gestagen combination; a calcitonin or analogue or derivative thereof, e.g. salmon, eel or human calcitonin parathyroid hormone or analogues thereof, e.g. PTH (1-84), PTH (1-34), PTH (1-36), PTH (1-38), PTH (1-31)NH2 or PPTS 893; a SERM (Selective Estrogen Receptor Modulator), e.g. raloxifene, lasofoxifene, TSE-434, FC1271, tibolone, vitamin D or an analog. Such additional bone active drugs may be administered more frequently than the bisphosphonate.
Appropriate pharmaceutical compositions are known in the art and have been described e.g. in US Patent Nos. 6,143,326 and 6,294,196, herein incorporated by reference. For the preparation of tablets, coated tablets, dragees or hard gelatine capsules the compounds of the present invention may be admixed with pharmaceutically inert, inorganic or organic excipients. Examples of suitable excipients for tablets, dragees or hard gelatine capsules include lactose, maize starch or derivatives thereof, talc or stearic acid or salts thereof.
The pharmaceutical compositions may also contain preserving agents, solubilising agents, stabilizing agents, wetting agents, emulsifiers, sweeteners, colorants, odorants, salts for the variation of osmotic pressure, buffers, coating agents or antioxidants. They may also contain other therapeutically valuable agents. Preferably, the pharmaceutical composition is a film coated tablet wherein the tablet core comprises 50 to 200 mg of a bisphosphonic acid or a pharmaceutically acceptable salt thereof as defined above and one or more pharmaceutically acceptable excipients selected from the group consisting of lactose, polyvinylpyrrolidone, macrocrystalline cellulose, crospovidone, stearic acid, silicon dioxide and the tablet core comprises one or more pharmaceutically acceptable excipients selected from the group consisting of hydroxypropyl methylcellulose, titanium dioxide, talc and polyethylene glycol 6000. These compositions are known in the art and described for example in US Patent Nos. 6,143,326 and 6,294,196.
Another aspect of the present invention is a method for treating, reducing or preventing disorders characterized by pathologically increased bone resorption comprising to a mammal administration of an effective amount of bisphosphonic acids or acceptable salts thereof. Especially the invention refers to a method for treating, reducing or preventing disorders characterized by pathologically increased bone resorption comprising oral administration of an effective amount of a bisphosphonic acid or a pharmaceutically acceptable salt thereof, wherein approximately 50 to 250 mg bisphosphonic acid or a pharmaceutically acceptable salt thereof are administered on one, two or three consecutive days per month. As noted above, the effective amount of bisphosphonic acid or pharmaceutically acceptable salt thereof may be administered as a single dose or as multiple sub-doses.
Preferably, in the method comprises administration of about 50 to 250 mg, preferably about 100 to 150 mg, of a bisphosphonate or a pharmaceutically acceptable salt thereof on one, two or three consecutive days per month. While the method includes administration of the dose through multiple sub-dosing, the preferred method provides a single dose. Examples for administration of the dose through multiple sub-dosing are as follows, if the efficacious dose is 150 mg, the dose may be two (2) 75 mg sub-doses administered on one day or on two consecutive days, or three (3) 50 mg sub-doses administered on one day or on two or three consecutive days; if the efficacious dose is 100 mg, the dose maybe two (2) 50 mg sub-doses administered on one day or two consecutive days, preferably on two consecutive days. The preferred bisphosphonate is ibandronate or a pharmaceutically acceptable salt thereof, e.g. ibandronic acid, monosodium salt, monohydrate.
Preferably, in the method according to the present invention, the bisphosphonic acid is selected from the group consisting of alendronate, cimadronate, clodronate, EB-1053, tiludronate, etidronate, ibandronate, incadronate, minodronate, neridronate, olpadronate, risedronate, piridronate, pamidronate, zolendronate or pharmaceutical acceptable salts thereof. More preferably, the bisphosphonic acid is ibandronate or a pharmaceutically acceptable salt thereof, e.g. ibandronic acid, monosodium salt, monohydrate.
The invention will now be explained with reference to exemplified embodiments.
EXAMPLES
EXAMPLE 1: Pharmaceutical composition
The Example shows the composition of a 50 mg tablet. The composition and preparation of these tablets is known in the art and described for example in US Patent Nos. 6,143,326 and 6,294,196.
Other compositions maybe prepared by adjusting the ingredients according to the amount of bisphosphonate, e.g. ibandronic acid, monosodium salt, monohydrate.
Figure imgf000011_0001

Claims

1. Use of a bisphosphonic acid or pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or the treatment of disorders characterized by pathologically increased bone resorption wherein the medicament a) comprises at least 120% of the expected efficacious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof; and b) the medicament is orally administered on one, two or three consecutive days per month.
2. The use of claim 1 wherein the disease is osteoporosis.
3. The use according to any of claims 1 to 2 wherein the efficacious dose is about 100 mg to about 150 mg of a bisphosphonic acid or a pharmaceutically acceptable salt thereof.
4. The use according to any of claims 1 to 3, wherein the bisphosphonic acid is ibandronic acid or a pharmaceutically acceptable salt thereof.
5. The use according to any of claims 1 to 4 wherein the efficacious dose is about 100 mg of a bisphosphonic acid or a pharmaceutically acceptable salt thereof.
6. The use according to any of claims 1 to 4 wherein the efficacious dose is about 150 mg of a bisphosphonic acid or a pharmaceutically acceptable salt thereof.
7. The use according to any one of claims 1 to 6, wherein the bisphosphonic acid or a pharmaceutically acceptable salt thereof is ibandronic acid, monosodium salt, monohydrate.
8. The use according to any one of claims 1 to 7, wherein the medicament is a film coated tablet wherein the tablet core comprises 50 to 250 mg of a bisphosphonic acid or a pharmaceutically acceptable salt thereof as defined in claims 1 to 7 and one or more pharmaceutically acceptable excipients selected from the group consisting of lactose, polyvinylpyrrolidone, macrocrystalline cellulose, crospovidone, stearic acid, silicon dioxide and the tablet core comprises one or more pharmaceutically acceptable excipients selected from the group consisting of hydroxypropyl mefhylcellulose, titanium dioxide, talc and polyethylene glycol 6000.
9. The use according to any of claims 1 to 8 wherein the medicament is administered as a single dose.
10. The use according to any of claims 1 to 8 wherein the medicament is administered as multiple sub-doses.
11. A method for treating or preventing disorders characterized by pathologically increased bone resorption comprising oral administration of an effective amount of a bisphosphonic acid or a pharmaceutically acceptable salt thereof, wherein 50 to 250 mg of a bisphosphonic acid or a pharmaceutically acceptable salt thereof is administered on one, or two consecutive days per month.
12. The method according to claim 11 wherein the bisphosphonic acid is ibandronic acid or a pharmaceutically acceptable salt thereof.
13. The method according to any of claims 11 and 12 wherein the bisphosphonic acid or a pharmaceutically acceptable salt thereof is administered as defined in any of claims 1 to 10.
13. The invention as hereinbefore defined.
PCT/EP2003/004629 2002-05-10 2003-05-02 Bisphosphonic acid for the treatment and prevention of osteoporosis WO2003095029A1 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
CA2481142A CA2481142C (en) 2002-05-10 2003-05-02 Bisphosphonic acids for the treatment and prevention of osteoporosis
DE60317061T DE60317061T2 (en) 2002-05-10 2003-05-02 IBANDRONIC ACID FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS
KR1020157010154A KR20150053811A (en) 2002-05-10 2003-05-02 Bisphosphonic acid for the treatment and prevention of osteoporosis
MXPA04009586A MXPA04009586A (en) 2002-05-10 2003-05-02 Bisphosphonic acid for the treatment and prevention of osteoporosis.
NZ535705A NZ535705A (en) 2002-05-10 2003-05-02 Ibandronic acid for the treatment and prevention of osteoporosis
AU2003229770A AU2003229770B2 (en) 2002-05-10 2003-05-02 Bisphosphonic acid for the treatment and prevention of osteoporosis
SI200331018T SI1506041T1 (en) 2002-05-10 2003-05-02 Ibandronic acid for the treatment and prevention of osteoporosis
EP03722591A EP1506041B1 (en) 2002-05-10 2003-05-02 Ibandronic acid for the treatment and prevention of osteoporosis
DK03722591T DK1506041T3 (en) 2002-05-10 2003-05-02 Inbandronic acid for the treatment and prevention of osteoporosis
JP2004503108A JP2005522526A (en) 2002-05-10 2003-05-02 Bisphosphonic acid for treatment and prevention of osteoporosis
BR0308901-0A BR0308901A (en) 2002-05-10 2003-05-02 bisphosphonic acids for osteoporosis treatment and prevention
KR1020137034838A KR20140021045A (en) 2002-05-10 2003-05-02 Bisphosphonic acid for the treatment and prevention of osteoporosis
KR1020047015694A KR100642961B1 (en) 2002-05-10 2003-05-02 Bisphosphonic acid for the treatment and prevention of osteoporosis
KR1020097019891A KR20090106663A (en) 2002-05-10 2003-05-02 Bisphosphonic acid for the treatment and prevention of osteoporosis
IL17437104A IL164371A0 (en) 2002-05-10 2004-06-09 Bisphosphonic acid for the treatment and prevention of osteoporosis
ZA2004/07950A ZA200407950B (en) 2002-05-10 2004-10-01 Bisphosphonic acid for the treatment and prevention of osteoporosis
HR20040906 HRP20040906B1 (en) 2002-05-10 2004-10-01 Bisphosphonic acid for the treatment and prevention of ostreoporosis
NO20044195A NO328734B1 (en) 2002-05-10 2004-10-01 Use of ibandronic acid for the manufacture of drugs for the treatment and prevention of osteoporosis
IL164371A IL164371A (en) 2002-05-10 2004-10-03 Use of ibandronic acid and pharmaceutical acceptable salts thereof for the manufacture of a medicament for treating or preventing disorders characterized by increased bone resorption
HK06100194.8A HK1080409A1 (en) 2002-05-10 2006-01-05 Bisphosphonic acid for the treatment and prevention of osteoporosis
NO20100477A NO331024B1 (en) 2002-05-10 2010-03-31 Use of risendronic acid for the prevention or treatment of osteoporosis
IL205262A IL205262A (en) 2002-05-10 2010-04-22 Use of risedronic acid or pharmaceutically acceptable salt thereof for the manufacture of a medicament for oral administration on one day per month for the prevention or the treatment of osteoporosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02010136.6 2002-05-10
EP02010136 2002-05-10

Publications (1)

Publication Number Publication Date
WO2003095029A1 true WO2003095029A1 (en) 2003-11-20

Family

ID=29414669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/004629 WO2003095029A1 (en) 2002-05-10 2003-05-02 Bisphosphonic acid for the treatment and prevention of osteoporosis

Country Status (33)

Country Link
US (5) US7410957B2 (en)
EP (4) EP1880744B1 (en)
JP (5) JP2005522526A (en)
KR (7) KR20090029312A (en)
CN (2) CN100551377C (en)
AR (2) AR039978A1 (en)
AT (1) ATE376444T1 (en)
AU (2) AU2003229770B2 (en)
BR (1) BR0308901A (en)
CA (2) CA2763775C (en)
CY (2) CY1108105T1 (en)
DE (1) DE60317061T2 (en)
DK (2) DK1880744T3 (en)
EC (1) ECSP045335A (en)
ES (2) ES2294277T3 (en)
GT (1) GT200300107A (en)
HK (1) HK1080409A1 (en)
HR (1) HRP20040906B1 (en)
IL (3) IL164371A0 (en)
MX (1) MXPA04009586A (en)
MY (2) MY146809A (en)
NO (2) NO328734B1 (en)
NZ (2) NZ535705A (en)
PA (1) PA8573101A1 (en)
PE (1) PE20040440A1 (en)
PL (2) PL371346A1 (en)
PT (2) PT1880744E (en)
RU (2) RU2387451C2 (en)
SI (2) SI1880744T1 (en)
TW (1) TWI347188B (en)
UY (1) UY27802A1 (en)
WO (1) WO2003095029A1 (en)
ZA (1) ZA200407950B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008507513A (en) * 2004-07-23 2008-03-13 ザ プロクター アンド ギャンブル カンパニー Risedronate composition and method of use
US7632829B2 (en) 2006-04-20 2009-12-15 Hoffmann-La Roche Inc. Diazepan derivatives
EP2210596A1 (en) 2009-01-22 2010-07-28 Laboratorios Liconsa, S.A. Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
EP1713489B1 (en) * 2004-08-23 2011-01-19 Teva Pharmaceutical Industries Ltd Crystalline form of ibandronate sodium and processes for preparation thereof
EP1596870B2 (en) † 2002-12-20 2011-04-06 F. Hoffmann-La Roche AG High dose ibandronate formulation

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
PL371264A1 (en) * 2001-12-21 2005-06-13 The Procter & Gamble Company Method for the treatment of bone disorders
US20030195171A1 (en) * 2002-04-05 2003-10-16 Daifotis Anastasia G. Method for inhibiting bone resorption with an alendronate and vitamin D formulation
NZ535705A (en) * 2002-05-10 2007-08-31 Hoffmann La Roche Ibandronic acid for the treatment and prevention of osteoporosis
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
ES2543804T3 (en) * 2005-02-01 2015-08-24 F. Hoffmann-La Roche Ag Ibandronate Polymorph B
AU2006210009B2 (en) * 2005-02-01 2009-08-13 F. Hoffmann-La Roche Ag Ibandronate polymorph A
US20070049557A1 (en) * 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
CN101437522A (en) * 2006-04-07 2009-05-20 默里昂研究Ⅲ有限公司 Solid oral dosage form containing an enhancer
US20100120723A1 (en) * 2006-12-20 2010-05-13 Mostafa Akbarieh Pharmaceutical composition comprising a hot-melt granulated lubricant
BRPI0912384A2 (en) * 2008-05-07 2015-10-13 Merrion Res Iii Ltd composition and method for preparing a composition
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
LT2459176T (en) 2009-07-31 2017-12-11 Grünenthal GmbH Crystallization method and bioavailability
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
KR20140026354A (en) 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 Pharmaceutical compositions of iron for oral administration
JP5874545B2 (en) * 2011-06-20 2016-03-02 アステラス製薬株式会社 Pharmaceutical composition for oral administration
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
CN107011380A (en) * 2016-01-28 2017-08-04 臧伟 A kind of diphosphonic acid derivative and containing diphosphonic acid derivative composition treatment fracture application
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143326A (en) * 1996-04-20 2000-11-07 Roche Diagnostics Gmbh Oral pharmaceutical preparation containing ibandronat
WO2001015703A1 (en) * 1999-09-02 2001-03-08 Merck & Co., Inc. Method for inhibiting bone resorption
US6294196B1 (en) * 1998-10-09 2001-09-25 Hoffmann-La Roche Inc. Pharmaceutical composition containing diphosphonic acid or salt thereof

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US124314A (en) * 1872-03-05 Improvement in preparing paper for buildings
US500937A (en) * 1893-07-04 Conduit railway insulator
DE2405254C2 (en) 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Use of 3-amino-1-hydroxypropane-1, 1-diphosphonic acid or its water-soluble salts for influencing calcium metabolic disorders in the human or animal body
DE2534391C2 (en) 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkane-1,1-diphosphonic acids
DE2745083C2 (en) 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonic acids and processes for their preparation
US4252742A (en) 1979-07-13 1981-02-24 Ciba-Geigy Corporation Chemical process for the preparation of 2,6-dialkylcyclohexylamines from 2,6-dialkylphenols
DE2943498C2 (en) 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Process for the preparation of 3-amino-1-hydroxypropane-1,1-diphosphonic acid
DE3016289A1 (en) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf METHOD FOR PRODUCING OMEGA-AMINO-1-HYDROXYALKYLIDEN-1,1-BIS-PHOSPHONIC ACIDS
IT1201087B (en) 1982-04-15 1989-01-27 Gentili Ist Spa PHARMACOLOGICALLY ACTIVE BIPPHOSPHONES, PROCEDURE FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS
FR2531088B1 (en) 1982-07-29 1987-08-28 Sanofi Sa ANTI-INFLAMMATORY PRODUCTS DERIVED FROM METHYLENEDIPHOSPHONIC ACID AND THEIR PREPARATION METHOD
US4509612A (en) 1982-09-28 1985-04-09 Applied Power Inc. Latch mechanism for a tilt-cab truck
JPS59145179A (en) 1983-01-11 1984-08-20 Ricoh Co Ltd Business machine enabled to detect supplementary part
IT1195993B (en) 1984-01-12 1988-11-03 Gentili Ist Spa PHARMACEUTICAL FORMS BASED ON DIPHOSPHONATES
DE3428524A1 (en) 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE3434667A1 (en) 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-DIMETHYLAMINO-1-HYDROXYBUTANE-1,1-DIPHOSPHONIC ACID, THEIR WATER-SOLUBLE SALTS, PROCESS FOR THEIR PRODUCTION AND THEIR USE
IT1196315B (en) 1984-10-29 1988-11-16 Gentili Ist Spa PROCEDURE FOR THE PREPARATION OF DIPHOSPHONIC ACIDS
US4812311A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
DE3512536A1 (en) 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3540150A1 (en) 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE3623397A1 (en) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE3626058A1 (en) 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE3640938A1 (en) 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THIS COMPOUND
DK126888A (en) 1987-03-10 1988-09-11 Yamanouchi Pharma Co Ltd BISPHOSPHONIC ACID DERIVATIVES AND THERAPEUTIC PREPARATIONS CONTAINING THESE COMPOUNDS
CA1339805C (en) 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
DE3822650A1 (en) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US4958839A (en) 1988-07-12 1990-09-25 Guzik Technical Enterprises, Inc. Disc clamp employing resilient cone for spreading balls
DE3825654A1 (en) * 1988-07-28 1990-02-01 Bosch Gmbh Robert SAFETY DEVICE ON A HAND MACHINE TOOL
JP2691914B2 (en) 1988-09-09 1997-12-17 株式会社リコー Image forming device
US5018651A (en) * 1988-12-27 1991-05-28 Hull Harold L Side or end dump article carrier
US4922077A (en) 1989-01-31 1990-05-01 Raytheon Company Method of laser marking metal packages
DE3917153A1 (en) * 1989-05-26 1990-11-29 Boehringer Mannheim Gmbh NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
JP2985205B2 (en) 1990-01-25 1999-11-29 ミノルタ株式会社 Image forming device
US5335048A (en) * 1990-01-30 1994-08-02 Minolta Camera Kabushiki Kaisha Efficient control system of image forming apparatus
JPH03226767A (en) 1990-01-31 1991-10-07 Minolta Camera Co Ltd Control system for image forming device
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
JPH04151765A (en) 1990-10-16 1992-05-25 Fujitsu Ltd System for automatically ordering consumables in facsimile equipment
AU661080B2 (en) * 1991-11-22 1995-07-13 Warner Chilcott Company, Llc Risedronate delayed-release compositions
JPH07502507A (en) 1991-12-17 1995-03-16 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド Method for treating osteoporosis using bisphosphonates and parathyroid hormone
JPH05224479A (en) 1992-02-10 1993-09-03 Toshiba Corp Image forming device
TW237386B (en) 1992-04-15 1995-01-01 Ciba Geigy
EP0648120B1 (en) 1992-06-30 1997-12-29 PROCTER & GAMBLE PHARMACEUTICALS, INC. Use of phosphonates for the treatment of osteoporosis
JPH06111039A (en) 1992-09-25 1994-04-22 Toray Ind Inc Recording method for optical read discrimination mark
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
JPH06250802A (en) 1993-02-22 1994-09-09 Ricoh Co Ltd Printer
FR2703590B1 (en) 1993-04-05 1995-06-30 Sanofi Elf USE OF BISPHOSPHONIC ACID DERIVATIVES FOR THE PREPARATION OF MEDICINES FOR PROMOTING BONE REPAIR.
US5510517A (en) * 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
JPH07239825A (en) 1994-02-28 1995-09-12 Canon Inc State informing method and network system using the same
TW390813B (en) 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US20010007863A1 (en) 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
JPH07325514A (en) 1994-05-30 1995-12-12 Ricoh Co Ltd Supply ordering system
JPH08152814A (en) 1994-11-30 1996-06-11 Mita Ind Co Ltd Control system for image forming device
JPH08152825A (en) 1994-11-30 1996-06-11 Mita Ind Co Ltd Control system for image forming device
FR2727629A1 (en) 1994-12-06 1996-06-07 Sanofi Sa OSTEOPOROSIS TREATMENT CYCLE KIT
JP3261900B2 (en) 1994-12-13 2002-03-04 村田機械株式会社 Facsimile machine
DE69534923T2 (en) 1994-12-28 2006-11-23 Gador S.A. ANABOLIC PREPARATION FOR BONE MASS CONTAINING OLPADRONATE
JPH08211792A (en) 1995-02-03 1996-08-20 Mita Ind Co Ltd Control system for image forming device
KR19980702210A (en) * 1995-02-17 1998-07-15 폴락 돈나 엘 How to reduce the risk of non-vertebral fractures
US20010051616A1 (en) * 1995-02-17 2001-12-13 David B. Karpf Method of lessening the risk of vertebral fractures
JPH08315052A (en) 1995-05-18 1996-11-29 Ricoh Co Ltd Automatic ordering system
JPH08310007A (en) * 1995-05-19 1996-11-26 Oki Data:Kk Serial printer
JPH09120238A (en) 1995-10-25 1997-05-06 Canon Inc Output device
JPH09156123A (en) 1995-12-04 1997-06-17 Brother Ind Ltd Printer
JPH09185474A (en) 1995-12-27 1997-07-15 Fuji Xerox Co Ltd Printing managing device
JP3363680B2 (en) 1995-12-28 2003-01-08 ブラザー工業株式会社 Cartridge authenticity discrimination method and output device using the same
JPH09259355A (en) 1996-03-21 1997-10-03 Oki Electric Ind Co Ltd Confirmation processing system for packaged product
US5930553A (en) * 1997-04-25 1999-07-27 Hewlett-Packard Company Image forming and office automation device consumable with memory
US5730715A (en) * 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
US5781405A (en) * 1996-09-30 1998-07-14 Gateway 2000, Inc. Electronic device having rotatably mounted infrared device with a pair of pegs fitting into a pair of holes
US6905701B2 (en) 1997-06-11 2005-06-14 Umd, Inc. Formulations for transmucosal vaginal delivery of bisphosphonates
US6572874B1 (en) * 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
ID24096A (en) 1997-07-22 2000-07-06 Merck & Co Inc METHODS FOR OBSTACLING BONE RESORTS
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
SE9703691D0 (en) 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
JP3065053B2 (en) * 1998-01-06 2000-07-12 セイコーエプソン株式会社 Device monitoring system, local monitoring device, integrated monitoring device, device monitoring method, and computer-readable medium storing program
WO1999067809A1 (en) 1998-06-24 1999-12-29 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
US6816968B1 (en) * 1998-07-10 2004-11-09 Silverbrook Research Pty Ltd Consumable authentication protocol and system
IT1303672B1 (en) 1998-07-28 2001-02-23 Nicox Sa NITRATED SALTS OF DRUGS ACTIVE IN BONE DISORDERS
US6494562B1 (en) * 1998-09-03 2002-12-17 Hewlett-Packard Company Method and apparatus for identifying a sales channel
FR2784031B1 (en) * 1998-10-02 2002-02-01 Sanofi Elf USE OF BISPHOSPHONIC ACID DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF LAMPS
EP0998933A1 (en) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Process for producing pharmaceutical compositions containing diphosphonates for oral administration
US6331533B1 (en) * 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
TR200101546T2 (en) * 1998-12-04 2001-11-21 Roche Diagnostics Gmbh Using ibandronate to improve bone integration in internal prostheses.
TW442666B (en) * 1998-12-22 2001-06-23 Minolta Co Ltd Zoom lens system
DE59902506D1 (en) * 1999-01-11 2002-10-02 Fraunhofer Ges Forschung MOS POWER COMPONENT AND METHOD FOR PRODUCING THE SAME
ES2211540T3 (en) 1999-04-09 2004-07-16 Karo Bio Ab RECEPTORS OF STROGENS AND BONE.
SE9901272D0 (en) 1999-04-09 1999-04-09 Astra Ab New improved formulation
CA2308532C (en) 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
AU775079B2 (en) 1999-05-21 2004-07-15 Novartis Ag Pharmaceutical compositions and uses
US6965411B1 (en) * 1999-06-24 2005-11-15 Jones Richard A Remote camera positioner
AR024462A1 (en) 1999-07-01 2002-10-02 Merck & Co Inc PHARMACEUTICAL TABLETS
US6903836B2 (en) * 1999-09-10 2005-06-07 Hewlett-Packard Development Company, L.P. Hard copy cost recovery systems, an apparatus for tracking usage information for a hard copy device, hard copy devices, and a usage accounting method
US6793934B1 (en) * 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US6285060B1 (en) * 1999-12-30 2001-09-04 Siliconix Incorporated Barrier accumulation-mode MOSFET
JP2001253827A (en) * 2000-02-15 2001-09-18 Pfizer Prod Inc Composition and method for treating osteoporosis
US20020004218A1 (en) * 2000-03-31 2002-01-10 Rodan Gideon A. Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase
WO2001076592A1 (en) 2000-04-06 2001-10-18 Acorda Therapeutics, Inc. Compositions and methods for promoting neural regeneration
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
GB0012209D0 (en) 2000-05-19 2000-07-12 Novartis Ag Organic compounds
HU228400B1 (en) * 2000-06-20 2013-03-28 Novartis Ag The use of bisphosphonates for treatment of osteoporosis
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
JP3563070B2 (en) * 2000-07-17 2004-09-08 山之内製薬株式会社 Oral absorption improving pharmaceutical composition
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
US6750213B2 (en) * 2000-10-19 2004-06-15 Merck & Co., Inc. Estrogen receptor modulators
CA2431515C (en) 2001-01-23 2008-01-22 Gador S.A. Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition, and use thereof
AR034199A1 (en) 2001-02-01 2004-02-04 Riderway Corp PHARMACOLOGICAL COMPOSITION LIQUID FOR THE TREATMENT OF OSEAS DISEASES AND PROCEDURES FOR THEIR ELABORATION
NZ527351A (en) 2001-02-06 2005-01-28 Royal Alexandra Hosp Children Use of bisphosphonate for the treatment of osteonecrosis and for the management of patients at risk of developing ostenonecrosis
NZ527157A (en) 2001-03-01 2005-04-29 Emisphere Tech Inc Compositions for delivering bisphosphonates
AU2002305359B2 (en) 2001-05-10 2005-05-26 Merck & Co., Inc. Estrogen receptor modulators
US6998678B2 (en) * 2001-05-17 2006-02-14 Infineon Technologies Ag Semiconductor arrangement with a MOS-transistor and a parallel Schottky-diode
WO2003051373A1 (en) 2001-12-13 2003-06-26 Merck & Co., Inc. Liquid bisphosphonate formulations for bone disorders
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
PL371264A1 (en) * 2001-12-21 2005-06-13 The Procter & Gamble Company Method for the treatment of bone disorders
DE10262418B3 (en) * 2002-02-21 2015-10-08 Infineon Technologies Ag MOS transistor means
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
AU2003218235B2 (en) * 2002-03-13 2008-05-15 Merck Sharp & Dohme Corp. Fluorinated 4-azasteroid derivatives as androgen receptor modulators
US20030195171A1 (en) 2002-04-05 2003-10-16 Daifotis Anastasia G. Method for inhibiting bone resorption with an alendronate and vitamin D formulation
NZ535705A (en) * 2002-05-10 2007-08-31 Hoffmann La Roche Ibandronic acid for the treatment and prevention of osteoporosis
DK1790347T3 (en) 2002-12-20 2015-01-19 Hoffmann La Roche Ibandronate high-dose-formulation
GB0424543D0 (en) * 2004-11-05 2004-12-08 Varintelligent Bvi Ltd Driving method for high frame rate display system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143326A (en) * 1996-04-20 2000-11-07 Roche Diagnostics Gmbh Oral pharmaceutical preparation containing ibandronat
US6294196B1 (en) * 1998-10-09 2001-09-25 Hoffmann-La Roche Inc. Pharmaceutical composition containing diphosphonic acid or salt thereof
WO2001015703A1 (en) * 1999-09-02 2001-03-08 Merck & Co., Inc. Method for inhibiting bone resorption

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAPURLAT ROLAND D ET AL: "Review of ibandronate in the treatment of osteoporosis.", EXPERT OPINION ON PHARMACOTHERAPY. ENGLAND MAR 2003, vol. 4, no. 3, March 2003 (2003-03-01), pages 391 - 396, XP009015325, ISSN: 1465-6566 *
DELMAS P D ET AL: "Daily and intermittent oral ibandronate provide significant reductions in vertebral fracture risk: Results from a large phase III Study.", CALCIFIED TISSUE INTERNATIONAL, vol. 72, no. 4, 20 April 2003 (2003-04-20), 30th European Symposium on Calcified Tissues;Rome, Italy; May 08-12, 2003, pages 332, XP001154326, ISSN: 0171-967X *
RIIS B J ET AL: "IBANDRONATE: A COMPARISON OF ORAL DAILY DOSING VERSUS INTERMITTENT DOSING IN POSTMENOPAUSAL OSTEOPOROSIS", JOURNAL OF BONE AND MINERAL RESEARCH, NEW YORK, NY, US, vol. 16, no. 10, October 2001 (2001-10-01), pages 1871 - 1878, XP001145829, ISSN: 0884-0431 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1596870B2 (en) † 2002-12-20 2011-04-06 F. Hoffmann-La Roche AG High dose ibandronate formulation
US7923028B2 (en) 2002-12-20 2011-04-12 Hoffman-La Roche Inc. High dose oral formulation of bisphosphonate and a process for making thereof
JP2008507513A (en) * 2004-07-23 2008-03-13 ザ プロクター アンド ギャンブル カンパニー Risedronate composition and method of use
JP2013231087A (en) * 2004-07-23 2013-11-14 Ajinomoto Co Inc Risedronate composition and its method of use
JP2015038135A (en) * 2004-07-23 2015-02-26 味の素株式会社 Risedronate composition and use method thereof
EP1713489B1 (en) * 2004-08-23 2011-01-19 Teva Pharmaceutical Industries Ltd Crystalline form of ibandronate sodium and processes for preparation thereof
EP1930011B1 (en) * 2004-08-23 2011-08-17 Teva Pharmaceutical Industries Ltd Crystalline form of ibandronate sodium
US7632829B2 (en) 2006-04-20 2009-12-15 Hoffmann-La Roche Inc. Diazepan derivatives
EP2210596A1 (en) 2009-01-22 2010-07-28 Laboratorios Liconsa, S.A. Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
WO2010084111A2 (en) 2009-01-22 2010-07-29 Laboratorios Liconsa, S.A. Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
WO2010084111A3 (en) * 2009-01-22 2010-10-07 Laboratorios Liconsa, S.A. Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof

Also Published As

Publication number Publication date
EP1506041A1 (en) 2005-02-16
CN1646193A (en) 2005-07-27
KR100642961B9 (en) 2021-11-12
GT200300107A (en) 2006-02-23
IL205262A (en) 2015-03-31
US20060166938A1 (en) 2006-07-27
BR0308901A (en) 2005-01-04
NZ556278A (en) 2009-06-26
US20080249069A1 (en) 2008-10-09
US20050075319A1 (en) 2005-04-07
NO20100477L (en) 2004-10-01
US20030225039A1 (en) 2003-12-04
CN1939314A (en) 2007-04-04
KR20090029312A (en) 2009-03-20
EP1880744A1 (en) 2008-01-23
AU2003229770B2 (en) 2009-11-05
RU2008103617A (en) 2009-08-10
PT1880744E (en) 2015-02-13
DE60317061D1 (en) 2007-12-06
JP5813911B2 (en) 2015-11-17
JP2009132709A (en) 2009-06-18
KR20150053811A (en) 2015-05-18
JP5837552B2 (en) 2015-12-24
CA2763775A1 (en) 2003-11-20
IL164371A0 (en) 2005-12-18
IL164371A (en) 2010-11-30
RU2387451C2 (en) 2010-04-27
NZ535705A (en) 2007-08-31
RU2004129324A (en) 2006-01-27
DE60317061T2 (en) 2008-07-24
HRP20040906A2 (en) 2005-06-30
CY1116233T1 (en) 2017-02-08
ES2294277T3 (en) 2008-04-01
KR20140021045A (en) 2014-02-19
RU2329809C2 (en) 2008-07-27
EP2851105A1 (en) 2015-03-25
JP2013166773A (en) 2013-08-29
EP1880744B1 (en) 2015-01-21
UY27802A1 (en) 2003-11-28
AR061845A2 (en) 2008-09-24
KR100642961B1 (en) 2006-11-10
ZA200407950B (en) 2005-12-28
AU2003229770A1 (en) 2003-11-11
ATE376444T1 (en) 2007-11-15
NO331024B1 (en) 2011-09-12
SI1506041T1 (en) 2008-02-29
TW200404553A (en) 2004-04-01
TWI347188B (en) 2011-08-21
PT1506041E (en) 2007-12-28
EP2308563A1 (en) 2011-04-13
KR20120065435A (en) 2012-06-20
JP2015083592A (en) 2015-04-30
SI1880744T1 (en) 2015-04-30
NO328734B1 (en) 2010-05-03
PE20040440A1 (en) 2004-08-07
PL371346A1 (en) 2005-06-13
CY1108105T1 (en) 2014-02-12
AU2010200438B2 (en) 2012-02-02
US20100197637A1 (en) 2010-08-05
KR20040097267A (en) 2004-11-17
AR039978A1 (en) 2005-03-09
DK1506041T3 (en) 2008-01-28
HK1080409A1 (en) 2006-04-28
MY140080A (en) 2009-11-30
US7192938B2 (en) 2007-03-20
CA2763775C (en) 2014-01-07
ECSP045335A (en) 2004-11-26
CA2481142C (en) 2012-11-13
US7718634B2 (en) 2010-05-18
KR20060058151A (en) 2006-05-29
NO20044195L (en) 2004-10-01
JP2005522526A (en) 2005-07-28
US7410957B2 (en) 2008-08-12
EP1506041B1 (en) 2007-10-24
PL399493A1 (en) 2012-11-05
KR20090106663A (en) 2009-10-09
ES2532393T3 (en) 2015-03-26
AU2010200438A1 (en) 2010-02-25
JP6067466B2 (en) 2017-01-25
PA8573101A1 (en) 2004-02-07
MY146809A (en) 2012-09-28
HRP20040906B1 (en) 2013-01-31
DK1880744T3 (en) 2015-02-09
CA2481142A1 (en) 2003-11-20
MXPA04009586A (en) 2005-01-11
JP2014058554A (en) 2014-04-03
CN100551377C (en) 2009-10-21

Similar Documents

Publication Publication Date Title
AU2010200438B2 (en) Bisphosphonic acid for the treatment and prevention of osteoporosis
AU2012202489B2 (en) Bisphosphonic acid for the treatment and prevention of osteoporosis
MX2011013867A (en) Biophosphonates useful for preventing and treating abnormal bone resorption.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1-2004-501498

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2003722591

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038075652

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2004/07950

Country of ref document: ZA

Ref document number: P20040906A

Country of ref document: HR

Ref document number: PA/a/2004/009586

Country of ref document: MX

Ref document number: 2194/CHENP/2004

Country of ref document: IN

Ref document number: 200407950

Country of ref document: ZA

Ref document number: 2481142

Country of ref document: CA

Ref document number: 2003229770

Country of ref document: AU

Ref document number: 1020047015694

Country of ref document: KR

Ref document number: 535705

Country of ref document: NZ

Ref document number: 2004503108

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004129324

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020047015694

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003722591

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003722591

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12008500064

Country of ref document: PH